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Dose-Dependent FateofVinyl Chloride and Its
Possible RelationshiptoOncogenicity in Rats
by P. G.Watanabe* and P. J.Gehring*
Studies on the fate of 14C-labeled vinyl chloride (VC) following oral administration and
inhalation exposure in rats demonstrated that the disposition of VC in the body is a
function of the dose. More importantly, from the data available, it appears that a corre-
lation exists between doses of VC which cause tumors and those that saturate metabolic
or detoxifying pathways. Additional studies characterized the depression of liver non-
protein sulfhydryl content (primarily GSH) with the duration and concentration of expo-
sure to VC. The results of these investigations indicate that statistical projections
utilizing data collected from rats exposed to high doses of VC are invalid for predicting
the hazard of low level exposure, because such projections violate the a priori assumption
that the dynamics governing the fate of VC in the body are unaltered.
Introduction
Once the carcinogenicity of a chemical has
been established a primary consideration is
the hazard of exposure to low levels of the
given chemical. Studies on the pharmacokinetic
and metabolic characteristics of such chemicals
are essential in accurately assessing the hazard
of low level exposures. Pharmacokinetics is the
study of the dynamic processes involved in the
absorption, distribution, metabolism and elim-
ination of chemicals from the body. Pharmaco-
kinetic studies alone are insufficient to assess
toxicity. However, their principal value is in
correlation of toxicity with the time-related dis-
position of chemicals in the body. An altered
disposition of a chemical in the body with dose
can explain in certain instances why toxicity,
including carcinogenicity, is produced at high
doses and not at low doses of the same chemi-
cal.
In the case of carcinogenicity, stochastic,
statistical projections are made from the range
of doses over which an increased incidence of
cancer can be measured to predict what per-
centage of individuals may respond at lower
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doses. Figure 1 shows a hypothetical cumula-
tive dose-response curve for the percentage of
individuals (triangles) in a population respond-
ing adversely in some manner to selected doses
of a chemical. The sigmoid curve represents a
response of a population described by a normal
or Gaussian distribution. These adverse re-
sponses (cancer) are discernible only over a
range of doses represented by the solid line,
because the investigator is limited by the num-
ber of individuals he can include in such a
study.
It should be emphasized that an a priori
assumption for making such projections is that
the chemical is handled in the same manner
by the body as the dose decreases. If the dy-
namics for the fate of the chemical change,
such extrapolation is not valid. Conceptually,
it is not surprising that toxicity (including
carcinogenicity) is expressed only after the
capacity to detoxify the chemical in the body
has been exceeded. In such cases, the response
of the population may be more accurately de-
scribed by the other two broken lines in the
lower left-hand corner of Figure 1. The most
important aspect is to determine if an altered
disposition of a chemical with dose functions
over a range from doses that cause toxicity to
those that do not cause toxicity.
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FIGURE 1. Plot of hypothetical log dose vs. per cent re-
sponse curve. Measurable responses are represented
by triangles. The sigmoid curve (--) represents a
population described by a normal distribution; in
theory the percentage responding never reaches zero
on the low end or 100% on the high end. The other
curves (- -) and (--) represent simulated responses
if there exists a threshold for the response.
In initial studies on the fate of vinyl chloride
(VC), rats were exposed in a closed recirculat-
ing inhalation chamber to varying concentra-
tions of VC (1). By monitoring the concentra-
tion of VC in the system by infrared spectro-
photometry, the rate of uptake of VC by the
rats was determined. Results on exposure to
low and high concentrations of VC and on pre-
treatment of the animals with metabolic in-
hibitors indicated that VC was metabolized by
at least two pathways. More importantly, it
appeared that the primary pathway for the
metabolism of VC became saturated as the
exposure concentration increased.
These initial results suggested a dose-de-
pendent fate of VC, and this motivated addi-
tional work to elucidate the fate of VC in rats
following both oral administration and inhala-
tion exposure. 14C-labeled VC was utilized in
subsequent investigations which greatly facili-
tated following the disposition of the admin-
istered VC.
Results and Discussion
Fate of VC Following Single Oral
Administration
Table 1 shows the percentage of 14C-activity
eliminated via various routes following differ-
ent single oral doses of VC in corn oil to rats
(2). The 14C-activity in urine, feces, and car-
cass and tissues represents nonvolatile metab-
olites of VC. If all the processes involved in
the disposition of VC in the body could be de-
scribed by first-order kinetics, implying that
the rates of the processes were proportional to
the amount of chemical available, then the
proportions of 14C activity eliminated by each
route of excretion would be the same over the
range of doses tested. If this were the case,
then the fate of VC in the body would be in-
dependent of the dose administered. However,
the results show that as the dose was increased
from 0.05 and 1.0 mg/kg to 20 or 100 mg/kg,
the percentage expired as VC increased mark-
edly, while the other parameters, particularly
urinary excretion of 14C-activity, decreased.
This demonstrates that the primary route for
the elimination of VC from the body is de-
pendent on the dose administered.
Since the urinary and pulmonary excretion
of VC were altered dramatically as the dose
increased from 1 to 100 mg/kg, the question
was raised whether these processes of elimina-
tion may be a function of dose. Figure 2 shows
a plot of the logarithm of the 14C-activity elim-
inated via the urine as a function of time.
Since the slopes or rates of elimination (t 1/2 =
4.5 hr) are unchanged, it must be concluded
that the rate of urinary excretion of nonvola-
tile metabolites of VC is unaltered by dose.
Figure 3 shows similarly the expiration of
VC following various doses. Elimination follow-
ing 0.05 or 1.0 mg/kg occurred in accordance
with a first-order rate or monoexponential proc-
ess with half-life of 53-58 min. When 100 mg/
kg was given, the elimination was biexponen-
tial. The initial phase of elimination had a
half-life of 14 min and was followed by a slower
phase with a t 1/2 of 41 min. The rates or t 1/2
times for elimination at the 100 mg/kg dose
correspond well with those reported by Withey
(3) for blood. These results are indicative of
a material which is bound reversibly to some
site in the body having a finite capacity. As the
dose increases, the availability of these binding
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FIGURE 2. "4C-activity excreted in the urine expressed
as percent of the dose administered (1 and 100 mg/
kg) vs. time. Each point represents the mean +
standard error of the mean for five rats. The initial
linear segments of the curves (12-36 hr) were fit by
linear regression analysis. t1/2 = 4.5 hr.
sites decreases and the chemical is free to find
its way to other sites or to be eliminated. Thus,
it may be concluded that the pulmonary excre-
tion of VC is not a rate-limiting step. Even
more importantly, the data indicate that the
state in which VC exists in the body changes
with dose.
Figure 4 summarizes the dose-dependent ex-
cretion of VC via urinary excretion (solid line)
and pulmonary elimination (broken line). The
area indicated by the rectangle represents the
range of doses where evidence of distributive
or metabolic saturation first occurs. Of par-
ticular significance is that in a current carcino-
genesis study in rats by Maltoni (4) daily oral
0
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doses of VC at 50 and 16.6 mg/kg-day have
resulted in 19% and 14% induction of hepatic
angiosarcoma, respectively, while at a dose of
3.33 mg/kg-day no tumors have been observed.
These results are after 85 weeks. Figure 4,
illustrating the occurrence of saturation as a
function of a single oral dose of VC, shows that
a correlation exists between doses of VC which
cause tumors and those that saturate meta-
bolic or detoxifying pathways. The dose-re-
sponse curve generated from the two higher
doses (50 and 16.6 mg/kg-day) predicts a 9%
tumor incidence at the 3.33 mg/kg-day level.
Since no tumors have been observed yet at
this low level, this is an example of the use
of pharmacokinetic data in interpretation of
why high doses of a chemical may produce toxi-
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FIGURE 3. Expired vinyl chloride expressed as percent
of the dose administered (0.05, 1, and 100 mg/kg) vs.
time. Each point represents the mean + standard
error of the mean of five rats. The linear phases of
the curves were fit by linear regression analysis.
October 1976 147Table 1. Percentage of administered 14C activity eliminated during 72 hr following a
single oral dose of vinyl chloride.
% of 14C activity a
0.05 mg/kg 1.0 mg/kg 20 mg/kg 100 mg/kg
Expired as
vC 1.4 ± 0.1 a 2.1 + 0.2 41.6 ± 5.7 66.6 ± 0.7
CO2 9.0 0.6 13.3 ±0.5 4.8 0.7 2.5 +0.1
Urine 68.3 ± 0.5 59.3 ± 2.8 22.6 ± 1.2 10.8 ± 1.0
Feces 2.4 ± 0.5 2.2 ± 0.4 1.0 ± 0.1 0.5 ± 0.1
Carcass and tissues 10.1 ± 1.9 11.1 ± 0.5 11.0 ± 2.7 1.8 ± 0.1
Total recovery 91.3 ± 2.5 88.8 ± 2.0 81.0 ± 2.9 82.3 ± 0.4
a Mean ± standard error, five rats/dose except three rats at 20 mg/kg level.
Table 2. Percentage of 14C activity eliminated during 72 hr following inhalation
exposure to 14C-vinyl chloride for 6 hr.a
% of 14C activitya
10 ppm 1000 ppm
Expired as
VC 1.61 + 0.16 (4) 12.26 ± 0.96 (814)
C02 12.09 ± 0.43 (30) 12.30 ± 0.63 (817)
Urine 67.97 ± 1.71 (169) 56.29 ± 1.96 (3739)
Feces 4.45 ± 0.22 (11) 4.21 ± 1.05 (280)
Carcass and tissues 13.84 ± 1.16 (34) 14.48 ± 0.52 (977)
Cage washb 0.15 0.08 (<1) 0.23 ±0.09 (15)
Total VC recovered, ,ug (248) (6642)
a Expressed as percentage of the total 14C-activity recovered. All values are means -+-
rats. Values in parenthesis are microgram equivalents of vinyl chloride.
b Water and acetone wash of the metabolism cage at termination of the experiment.
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FIGURE 4. Summary of the dose-dependent excretion of
VC: ( ) urinary excretion; (--) pulmonary elim-
ination. Urinary excretion represents polar metabo-
lites of VC while pulmonary elimination is VC per se.
Area demarcated by the rectangle represents range
of doses over which distributive and metabolic sat-
uration occurs.
standard error from four
city and extrapolation of the same toxic effect
at lower levels is invalid because the fate of
the chemical has changed.
Fate of VC Following Inhalation Exposure
Table 2 shows the fate of 14C-VC in rats
exposed for 6 hr to 10 or 1000 ppm VC (5). Im-
mediately following the exposure, the rats were
placed in cages providing for collection of
14C-activity in the expired air, feces, and urine
over the subsequent 72 hr. As in the experi-
ments in which oral doses were given, the
percentage of 14C-activity expired as VC in-
creased as the exposure increased.
Also to be noted in Table 2 is that the per-
centage 14C-activity in the tissues and carcass
increases slightly as the exposure is increased
from 10 to 1000 ppm. Although not statistically
significant, this is remarkable because a much
larger fraction was expired as VC. In partic-
ular, the normalized amount of 14C-activity in
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148the liver and skin increased. This may mean
that a larger fraction is being bound to the
macromolecules of the tissues. This aspect is
currently being investigated, since such reac-
tivity may explain the carcinogenic effect of
vC.
Figures 5 and 6 show respectively the elim-
ination of "4C-nonvolative metabolites in the
urine and VC per se in the expired air. Neither
elimination process is rate-limiting or over-
whelmed by increasing the exposure concentra-
tion. However, it is noteworthy that expired
VC increased with increasing dose, whereas
excretion of urinary metabolites decreased,
suggesting a saturation of the metabolism of
VC. The results of these studies as those of
previous studies support the conclusions that
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Each point represents the mean -+- standard error
of the mean for four rats. The initial log linear phase
of the curves (12-36 hr) were fit by linear regression
analysis.
(1) the fate of VC changes with dose and (2)
this occurs because the primary pathway for
the metabolism of VC is saturated at high
doses or exposures.
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FIGURE 6. Expired vinyl chloride expressed as percent-
age of the recovered radioactivity vs. time following
a 6-hr. exposure to 10 and 1000 ppm VC. Each point
represents the mean + standard error of the mean
of four rats. The curves were fit by linear regression
analysis.
Since the metabolism of VC appears to occur
via at least two pathways, an effort was made
to identify the urinary metabolites of VC. Al-
ready it had been demonstrated that a meas-
urable amount of VC was metabolized to CO2.
Using high-pressure liquid chromatography,
three major metabolites have been isolated
from urine. Two of the three have been iden-
tified by gas chromatography-mass spectro-
scopy. These are metabolite A, N-acetyl-S(2-
hydroxyethyl)cysteine, and metabolite B, is
thiodiglycolic acid. Together these metabolites
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149comprise 50 to 60% of the radioactivity found
in urine. A third metabolite, comprising 35%
of the metabolites present in the urine has
been isolated but remains unidentified. Both
metabolites A and B are likely formed from
S-(2-hydroxyethyl) cysteine. At one time, it
appeared that the third major urinary meta-
bolite, comprising about 30% of the radio-
activity, was S- (2-hydroxyethyl)cysteine. Al-
though some analytical comparisons between
the isolated metabolite and 2-hyroxyethylcys-
teine favored this conclusion, other failed to
confirm the identity of this metabolite.
Identification of these metabolites of VC in
urine indicates that VC is transformed in the
body to a reactive intermediate metabolite,
which is then detoxified by reaction with gluta-
thione, (GSH, y-glutamylcysteinylglycine).
Subsequently, the glutamic acid and glycine
moieties of the tripeptide are cleaved, and the
cysteine conjugate of the reactive metabolite
of VC is either acetylated or further oxidized
and excreted as the aforementioned metabolites.
The urinary metabolites of VC were not
changed either qualitatively or quantitatively
as the dose or exposure level was increased.
Since evidence has been presented for several
metabolic pathways being involved in the bio-
transformation of VC, the lack of alteration
in the urinary metabolites with dose may seem
inconsistent. However, it should be emphasized
that toxicity is a result of the balance between
the relative rates of intoxicating to detoxificat-
ing metabolic pathways, and while this param-
0
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eter may change with dose it need not be
reflected by the urinary metabolites which con-
stitute ultimate end products of metabolism.
Our initial work and subsequently that of
others (6-8) indicates that one pathway in-
volves oxidation of VC by microsomal enzymes
to chloroethylene oxide. Other pathways which
involve either nonenzymatic or enzymatic con-
jugation with GSH, mediated by soluble en-
zymes, and dechlorination reactions, mediated
by both soluble and microsomal enzymes, are
all possibly involved in the overall metabolism
of VC. The relative contribution of these en-
zyme systems in the metabolism of VC are
currently under investigation.
Depression of Hepatic Nonprotein Sulfhydryl
Content by VC
A very important aspect of the metabolism
of VC is the detoxification reaction with hepatic
nonprotein sulfhydryl groups (composed of
primarily GSH). When high doses of some
chemicals, for example bromobenzene and
acetaminophen, are given, the glutathione is
used up at a faster rate than it can be produced
by conjugation with the reactive intermediates.
As the level of glutathione in the liver is pro-
gressively depleted, the reactive metabolites
react with macromolecules such as protein,
DNA and RNA leading to toxicity (9, 10).
Generally, it is accepted that one mechanism
for chemical carcinogenesis may involve such
reactions.
To assess the effect of VC exposures on
hepatic glutathione levels, rats were exposed
to concentrations of 10, 50, 150, 250, 1000, or
2000 ppm for 1-7 hr (11). The results are
shown in Figure 7. Exposure to 150, 250, 1000,
or 2000 ppm VC caused a progressive depres-
sion of the hepatic nonprotein sulfhydryl con-
tent. Exposure to 50 ppm for 7 hr produced a
small and inconsistent depression. No depres-
sion was observed in rats exposed to 10 ppm
VC. These results indicate that there is a
measurable biological threshold for the depres-
sion of hepatic glutathione levels induced by
exposures to vinyl chloride. Unequivocal de-
pressions are produced by concentrations ex-
ceeding 50 ppm, while exposure to 50 ppm
seems to be a transition zone and exposure to
10 ppm causes no depression.
How do these results relate to the carcino-
genicity of VC? In the studies of Maltoni and
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FIGURE 7. Depression of hepatic nonprotein sulfhydryl
content vs. duration of exposure to 2000, 1000, 250,
150, 50, and 10 ppm vinyl chloride. Each point repre-
sents the mean + standard error of five animals ex-
cept the point for 50 ppm which represents 25 ani-
mals. The asterisks (*) represent values statistically
different from controls (p < 0.05).
Lefemine (12), the reported incidence of angio-
sarcoma of the liver in rats exposed 4 hr/day,
5 days/week to 2500 or 6000 ppm was 22%.
The incidence in rats exposed to 500 and 250
ppm were, respectively, 12 and 7%. Reference
to Figure 7 indicates that the depression of
the hepatic nonprotein sulfhydryl content ob-
served after 4 hr of exposure coincides with
the increased incidence of angiosarcoma.
In the same study (12) an incidence of only
2%o angiosarcoma of the liver occurred in rats
exposed to 50 ppm VC. As indicated previously,
exposure to 50 ppm for 7 hr caused a small and
inconsistent depression of the hepatic nonpro-
tein sulfhydryl content. This exposure appeared
to be in the transition zone of the threshold for
this biological effect. In a recent publication by
Maltoni (13), not only the incidences of angio-
sarcomas of the liver were given but also the
latency periods for their development were pro-
vided. The latency periods were 64, 70, 78, 81,
and 79 weeks in rats exposed to 10,000, 6000,
2500, 500, and 250 ppm, respectively. In rats
exposed to 50 ppm, the latency period was 135
weeks. Indeed tumors were discovered in these
aged rats when they were killed at the end of
the study. Since the tumors in the former
groups of rats were discovered as they died
spontaneously, the discrepancy is even greater
than the values indicate. The latency period for
the development of other types of tumors
showed the same discrepancy. Consideration of
these results leads to the conclusion that, in
rats, exposure to 50 ppm VC 4 hr/day is in the
threshold transition zone for not only hepatic
nonprotein free sulfhydryl depression but for
tumor induction as well.
Conclusion
In summarizing the studies on the pharmaco-
kinetics and metabolism of VC, the data indi-
cate that the fate of VC in rats is dose-depen-
dent following either single oral administration
or inhalation exposure. More importantly, it
appears from the data available that a correla-
tion exists between doses of VC that cause tu-
mors and those that saturate metabolic or de-
toxifying pathways.
The primary detoxification pathway for VC
involves conjugation of its reactive metabolites
with nonprotein sulfhydryl groups. Therefore,
it seems reasonable to postulate that as the
nonprotein sulfhydryl groups are depleted, re-
active metabolites will be free to react with
other macromolecules (DNA, RNA, protein, li-
pids), resulting in toxicity and carcinogenicity.
Recent reports have demonstrated that in the
presence of fortified microsomal enzyme prepa-
rations reactive metabolites of VC are produced
which covalently bind to rat liver microsomes
(6), protein sulfhydryl groups, RNA (7), and
adenosine of DNA (8). Inclusion of glutathione
in the system will decrease or preclude these
reactions depending on the concentration. It is
highly significant that exposure to 10 ppm VC
for 7 hr caused no depression of hepatic non-
protein sulfhydryl content. This indicates that
there is a threshold of exposure in rats at
which the ability to replace sulfhydryl groups
is not overwhelmed and physiologic defense
mechanisms remain fully operative. Further-
October 1976 151more, this suggests that thresholds exist for
toxic effects which are expressed with greater
intensity as this protective mechanism is de-
pressed. Studies currently in progress are de-
signed to characterize the in vivo macromolecu-
lar binding of VC to protein and nucleic acids
following exposure to various concentrations of
14C_VC.
Finally, it must be emphasized strongly that
stochastic, statistical projections utilizing data
collected from rats exposed to high doses of VC
are invalid for predicting the hazard of low
level exposures. Such projections violate the a
priori assumption that the dynamics governing
the fate of the compound are unaltered.
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